Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.

Literature DB >> 10465182

Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.

N Sattar, M Perera, M Small, M A Lumsden.

Abstract

C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
C-Reactive Protein

Year: 1999 PMID： 10465182 DOI： 10.1016/S0140-6736(99)02079-6

Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321

Keyword Cloud
Cited

7 in total

1. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Authors: M Lazzeroni; D Macis; A Decensi; S Gandini; M T Sandri; D Serrano; A Guerrieri-Gonzaga; H Johansson; S Mora; C Daldoss; U Omodei; B Bonanni
Journal: Ecancermedicalscience Date: 2008-02-06

Review 2. Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials.

Authors: Karin Meissner; Hans Distel; Ulla Mitzdorf
Journal: BMC Med Date: 2007-03-19 Impact factor: 8.775

Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.

1. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Review 2. Evidence for placebo effects on physical but not on biochemical outcome parameters: a review of clinical trials.

3. Do we need clinical trials to test the ability of transdermal HRT to prevent coronary heart disease?

4. What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women?

5. Dual-port distal gastrectomy for the early gastric cancer.

Review 6. Role of C-Reactive Protein at Sites of Inflammation and Infection.

7. Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies.